Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer
A phase 2 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.
Overview
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer is a phase 2 interventional study registered as NCT03315754 by Steba Biotech S.A., with 50 participants recorded, started 2017-10-02 and reaching its primary completion in 2020-11-02. Interventions recorded: TOOKAD Soluble 4 mg/kg. Conditions recorded: Localized Prostate Cancer.
Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
- TrialEfficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.